Pangenomic Health Inc.
NARA
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -88.86% | -24.48% | 134.07% | 122.29% | 438.85% |
| Gross Profit | 88.86% | 24.48% | -134.07% | -122.29% | -438.85% |
| SG&A Expenses | 532.04% | 1,245.75% | 70.86% | 52.90% | -72.53% |
| Depreciation & Amortization | 0.00% | -93.33% | -95.65% | -95.65% | -95.65% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.19% | 803.52% | 78.78% | 92.21% | -2.06% |
| Operating Income | -49.19% | -803.52% | -78.78% | -92.21% | 2.06% |
| Income Before Tax | -3.48% | -783.23% | 84.56% | -71.97% | -48.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.48% | -783.23% | 84.56% | -71.97% | -48.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.48% | -783.23% | 84.56% | -71.97% | -48.60% |
| EBIT | -49.19% | -803.52% | -78.78% | -92.21% | 2.06% |
| EBITDA | -49.20% | -814.87% | -81.23% | -95.29% | 1.49% |
| EPS Basic | 78.45% | -263.72% | 93.80% | 50.06% | 43.37% |
| Normalized Basic EPS | 68.28% | -261.27% | 39.72% | 50.10% | 61.61% |
| EPS Diluted | 77.16% | -263.72% | 93.80% | 50.06% | 42.16% |
| Normalized Diluted EPS | 68.28% | -261.27% | 39.72% | 50.10% | 61.61% |
| Average Basic Shares Outstanding | 380.22% | 143.42% | 149.00% | 244.55% | 162.36% |
| Average Diluted Shares Outstanding | 380.22% | 143.42% | 149.00% | 244.55% | 162.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |